# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
RBC Capital analyst Gregory Renza reiterates Spruce Biosciences (NASDAQ:SPRB) with a Sector Perform and maintains $2 price t...
Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(...
Oppenheimer analyst Hartaj Singh maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target fr...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive di...
Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels a...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.